Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation

Optimizing SG&A Costs: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and Dynavax Technologies Corporation have taken different paths in optimizing these costs.

Gilead Sciences, Inc.: A Steady Climb

From 2014 to 2023, Gilead Sciences has seen a consistent increase in SG&A expenses, peaking at $6.09 billion in 2023. This represents a 104% increase from 2014, reflecting their expansive growth and investment in administrative capabilities.

Dynavax Technologies Corporation: A Rapid Surge

Dynavax, on the other hand, has experienced a more dramatic rise, with SG&A expenses growing by 760% over the same period, reaching $152.9 million in 2023. This surge indicates aggressive scaling and strategic investments in their operational framework.

Both companies showcase unique strategies in managing SG&A costs, offering valuable insights into their operational priorities and market positioning.